Nucleoside reverse transcriptase inhibitors (NRTIs) for chronic hepatitis BExamples| Generic Name | Brand Name |
|---|
| adefovir | Hepsera | | entecavir | Baraclude | | lamivudine | 3TC, Heptovir | | telbivudine | Sebivo |
How It WorksNucleoside reverse transcriptase inhibitors (NRTIs) are medicines
that slow the ability of the
hepatitis B virus (HBV) to multiply in the body. They
are taken as pills once a day for at least a year, and usually much longer.
Adefovir, entecavir, lamivudine, and telbivudine are approved by
Health Canada for use in adults. Why It Is UsedNRTIs are used to treat long-term (chronic) HBV infection in adults
who are at risk for liver disease. The Canadian Association for the Study of
the Liver has made
recommendations on who should receive treatment for
chronic hepatitis B based on the presence of hepatitis B
antigens in your blood, the level of
hepatitis B virus DNA (HBV DNA) in your blood, and the
levels of your liver
enzymes.1 How Well It WorksTreatment for HBV infection is considered successful if blood tests
show that the virus is no longer multiplying in the body, if liver enzyme
levels return to normal, and if liver damage (such as
inflammation and scarring) improves. NRTIs work in
most of the people who take them, but
relapse (the virus starts to multiply again) is common
after a medicine is stopped, so you may have to take the medicine for a long
time.2, 3 The hepatitis B virus may develop
resistance to some of the NRTIs:2 - After 1 year of treatment with lamivudine, up to one-third of
hepatitis B viruses may be resistant to the medicine. After 5 years of
treatment, up to 70% of HBV may be resistant to
lamivudine.
- Resistance is less of a problem with telbivudine than
with lamivudine. But resistance to telbivudine goes up greatly after one year
of treatment.
- Resistance is less of a problem with adefovir. After
5 years of adefovir treatment, less than one-third of HBV may be resistant to
the medicine.
- Resistance is rare with entecavir, especially when it
is used as the first medicine to treat hepatitis B. It is slightly more common
when entecavir is used after lamivudine treatment.
Side EffectsNRTIs rarely have side effects. If you have any side effects, they
may include: - Fever.
- Feeling tired or
weak.
- Headache.
- Sore
throat.
- Diarrhea.
- Dizziness.
- Pain in your
belly or back.
Adefovir may harm your kidneys if you are at risk for or have a
kidney problem. In rare cases, NRTIs have led to severe liver problems or to a
buildup of acid in the blood (lactic acidosis). Call your doctor if you develop
any symptoms of these problems such as: - Unusual muscle pain.
- Belly
pain.
- Nausea.
- Feeling
cold.
- Dizziness.
- A fast
heartbeat.
- Yellowing of your skin or the whites of your eyes (jaundice).
- Light-coloured stools.
See Drug Reference for a full list of side effects. (Drug Reference
is not available in all systems.) What To Think About- It is important to talk to your doctor about
all the medicines and herbal remedies you are taking. These may affect how well
your medicine for chronic hepatitis B works.
- After treatment with
any type of NRTI is stopped, your infection may come back (relapse), and you
may need to start taking the same or a different medicine
again.
- Lamivudine was the first NRTI approved to treat chronic
hepatitis B. It is safe for people who have significant
cirrhosis or who have a weakened
immune system from another health problem. It also can
be used for pregnant women if the benefits outweigh the risks.
- The
choice of NRTI depends upon how well it works, its safety, costs, and side
effects:
- Lamivudine costs less than adefovir and entecavir.
Lamivudine also costs less than interferons, but you will end up taking it for
a longer time than if you were taking interferons.
- Some studies of
entecavir show that it works better than lamivudine or adefovir.4, 5
- Lamivudine should be used for at least 1 year. If
lamivudine is used for a long time, the hepatitis B virus may become
resistant and no longer respond to the
medicine.
- Adefovir is effective against HBV infections that have
become resistant to lamivudine, but adefovir costs more than
lamivudine.2 A study showed that treatment with
adefovir worked better for some people with chronic hepatitis B if the medicine
was taken for 144 weeks than if it was taken for only 48 weeks.6
- Resistance is not as big a problem for adefovir
and entecavir as it is for lamivudine.
- Entecavir was approved by
Health Canada in 2006, so experts do not yet know the long-term effects of this
medicine or how long it should be used.
- Telbivudine was approved by
Health Canada in 2006, so experts do not yet know the long-term effects of this
medicine or how long it should be used. Studies have shown that telbivudine
works better than lamivudine.7 But telbivudine is more
expensive than lamivudine and may have similar problems with resistance.
- There have been some studies combining lamivudine
with peginterferon. The studies have had different results about how well
combining these medicines works compared to using only one medicine.8, 9
- Adefovir may affect how
well medicines for
HIV work.
- NRTIs may get into breast milk
and so are not thought to be safe for babies whose mothers are breast-feeding.
- Some NRTIs approved to treat HIV are being used to treat hepatitis
B infections that have become resistant to lamivudine, adefovir, entecavir, or
telbivudine.
Complete the
new medication information form (PDF) (What is a PDF document?)
to help you understand this medication.
| | Author: | Douglas Dana Maria G. Essig, MS, ELS | Last Updated: February 8, 2008 | | Medical Review: | Anne C. Poinier, MD - Internal Medicine Kathleen Romito, MD - Family Medicine W. Thomas London, MD - Hepatology Jerome B. Simon, MD, FRCPC, FACP - Gastroenterology | © 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
| 
| |
| |